Drugs / TSL2109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07514065 | Feb → Dec 2026 expected | castration-resistant prostate carcinoma | Tasly Pharmaceutical Group Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSL2109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07514065 ↗ |
| Action | Inhibit | “This product is a selective small-molecule inhibitor of DYRK2 and CDK4/6 based on novel anticancer targets, novel chemical structure, and novel mechanism of action.” NCT07514065 ↗ |
| Modality | Small molecule | “As a small-molecule inhibitor with novel targets, structure and mechanism, TSL2109 blocks tumor cell cycle progression independently of hormonal signaling.” NCT07514065 ↗ |
| Route | Oral | “Administered orally under fasting conditions.” NCT07514065 ↗ |